Hematopoietic Stem Cell Transplant for Immune Deficiency and Immune Dysregulation Disorders

Immunology and Allergy Clinics of North America

Volumn 35, Issue 4, 2015, Pages 695-711

  Hagin, David ^a,b,c   Burroughs, Lauri ^a,b,d   Torgerson, Troy R ^a,b,c  

^a SEATTLE CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

BMT; Conditioning; GVHD; GVT; HSCT; PIDD; Rejection

Indexed keywords

I KAPPA B KINASE ALPHA; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; PERFORIN; TRANSCRIPTION FACTOR GATA 2;

ADENOSINE DEAMINASE DEFICIENCY; ADENOSINE DEAMINASE DEFICIENCY TYPE II; AUTOSOMAL DOMINANT HYPERIMMUNOGLOBULIN E SYNDROME; CHRONIC GRANULOMATOUS DISEASE; CLINICAL EFFECTIVENESS; COMMON VARIABLE IMMUNODEFICIENCY; CYTOTOXIC T LYMPHOCYTE ASSOCIATED PROTEIN 4; DEDICATOR OF CYTOKINESIS 8 DEFICIENCY; DIGEORGE SYNDROME; DONOR SELECTION; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; GRISCELLI SYNDROME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; I KAPPA B KINASE ALPHA DEFICIENCY; IKBA DEFICIENCY; IMMUNE DEFICIENCY; IMMUNE DYSREGULATION; INTERLEUKIN 10 DEFICIENCY; INTERLEUKIN 10 RECEPTOR DEFICIENCY; INTERLEUKIN 2 RECEPTOR ALPHA DEFICIENCY; LEUKOCYTE ADHESION DEFICIENCY; LIPOPOLYSACCHARIDE RESPONSIVE AND BEIGE LIKE ANCHOR PROTEIN DEFICIENCY; NIJMEGEN BREAKAGE SYNDROME; PERFORIN DEFICIENCY; PHOSPHOGLUCOMUTASE 3 DEFICIENCY; PRIORITY JOURNAL; REVIEW; SEVERE CONGENITAL NEUTROPENIA; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 GAIN OF FUNCTION DEFICIENCY; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 GAIN OF FUNCTION DEFICIENCY; TRANSCRIPTION FACTOR GATA 2 DEFICIENCY; WARTS HYPOGAMMAGLOBULINEMIA; WISKOTT ALDRICH SYNDROME; X LINKED AGAMMAGLOBULINEMIA; X LINKED HYPERIMMUNOGLOBULIN M SYNDROME; X LINKED LYPHOPROLIFERATIVE DISEASE TYPE I; X LINKED LYPHOPROLIFERATIVE DISEASE TYPE II; X LINKED THROMBOCYTOPENIA; ADVERSE EFFECTS; CYTOLOGY; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL; HISTOCOMPATIBILITY; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGY; PROCEDURES; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

DONOR SELECTION; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 84943814197     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2015.07.010     Document Type: Review

References (62)

1. Bortin M.M. A compendium of reported human bone marrow transplants. Transplantation 1970, 9(6):571-587.
2. Gatti R., Meuwissen H., Allen H., et al. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968, 292(7583):1366-1369.
3. Bach F., Albertini R., Joo P., et al. Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet 1968, 292(7583):1364-1366.
4. Martinez C.A., Shah S., Shearer W.T., et al. Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. J Allergy Clin Immunol 2012, 129(1):176-183.
5. Güngör T., Teira P., Slatter M., et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet 2014, 383(9915):436-448.
6. Marsh R.A., Rao M.B., Gefen A., et al. Experience with alemtuzumab, fludarabine, and melphalan reduced-intensity conditioning hematopoietic cell transplantation in patients with nonmalignant diseases reveals good outcomes and that the risk of mixed chimerism depends on underlying disease, stem cell source, and alemtuzumab regimen. Biol Blood Marrow Transplant 2015, 21(8):1460-1470.
7. Komanduri K.V., St John L.S., de Lima M., et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood 2007, 110(13):4543-4551.
8. Welte K., Foeken L., Gluckman E., et al. International exchange of cord blood units: The registry aspects. Bone Marrow Transplant 2010, 45(5):825-831.
9. Brunstein C.G., Fuchs E.J., Carter S.L., et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011, 118(2):282-288.
10. Devine S.M., Vij R., Rettig M., et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008, 112(4):990-998.
11. Anasetti C., Logan B.R., Lee S.J., et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012, 367(16):1487-1496.
12. Reisner Y., Kapoor N., O'Reilly R.J., et al. Allogeneic bone marrow transplantation using stem cells fractionated by lectins: VI, in vitro analysis of human and monkey bone marrow cells fractionated by sheep red blood cells and soybean agglutinin. Lancet 1980, 2(8208-8209):1320-1324.
13. Reisner Y., Kapoor N., Kirkpatrick D., et al. Transplantation for severe combined immunodeficiency with HLA-A, B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells. Blood 1983, 61(2):341-348.
14. Schumm M., Lang P., Bethge W., et al. Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device. Cytotherapy 2013, 15(10):1253-1258.
15. Lang P., Feuchtinger T., Teltschik H., et al. Improved immune recovery after transplantation of TCRαβ/CD19-depleted allografts from haploidentical donors in pediatric patients. Bone Marrow Transplant 2015, 50:S6-S10.
16. Ghosh S., Schuster F.R., Adams O., et al. Haploidentical stem cell transplantation in DOCK8 deficiency - successful control of pre-existing severe viremia with a TCRass/CD19-depleted graft and antiviral treatment. Clin Immunol 2014, 152(1-2):111-114.
17. Neven B., Leroy S., Decaluwe H., et al. Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. Blood 2009, 113(17):4114-4124.
18. Hassan A., Lee P., Maggina P., et al. Host natural killer immunity is a key indicator of permissiveness for donor cell engraftment in patients with severe combined immunodeficiency. J Allergy Clin Immunol 2014, 133(6):1660-1666.
19. Ozsahin H., Cavazzana-Calvo M., Notarangelo L.D., et al. Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood 2008, 111(1):439-445.
20. Moratto D., Giliani S., Bonfim C., et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood 2011, 118(6):1675-1684.
21. Clave E., Busson M., Douay C., et al. Acute graft-versus-host disease transiently impairs thymic output in young patients after allogeneic hematopoietic stem cell transplantation. Blood 2009, 113(25):6477-6484.
22. Cavazzana-Calvo M., Andre-Schmutz I., Dal Cortivo L., et al. Immune reconstitution after haematopoietic stem cell transplantation: obstacles and anticipated progress. Curr Opin Immunol 2009, 21(5):544-548.
23. Di Ianni M., Falzetti F., Carotti A., et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011, 117(14):3921-3928.
24. Kwan A., Abraham R.S., Currier R., et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the united states. JAMA 2014, 312(7):729-738.
25. Grossman J., Cuellar-Rodriguez J., Gea-Banacloche J., et al. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. Biol Blood Marrow Transplant 2014, 20(12):1940-1948.
26. Cuellar-Rodriguez J., Gea-Banacloche J., Freeman A.F., et al. Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. Blood 2011, 118(13):3715-3720.
27. Rossi A., Borroni R.G., Carrozzo A.M., et al. Griscelli syndrome type 2: long-term follow-up after unrelated donor bone marrow transplantation. Dermatology 2009, 218(4):376-379.
28. Schuster F., Stachel D.K., Schmid I., et al. Griscelli syndrome: report of the first peripheral blood stem cell transplant and the role of mutations in the RAB27A gene as an indication for BMT. Bone Marrow Transplant 2001, 28(4):409-412.
29. Burroughs L.M., Torgerson T.R., Storb R., et al. Stable hematopoietic cell engraftment after low-intensity nonmyeloablative conditioning in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. J Allergy Clin Immunol 2010, 126(5):1000-1005.
30. Rao A., Kamani N., Filipovich A., et al. Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. Blood 2007, 109(1):383-385.
31. Qasim W., Cavazzana-Calvo M., Davies E.G., et al. Allogeneic hematopoietic stem-cell transplantation for leukocyte adhesion deficiency. Pediatrics 2009, 123(3):836-840.
32. Thomas C., Le Deist F., Cavazzana-Calvo M., et al. Results of allogeneic bone marrow transplantation in patients with leukocyte adhesion deficiency. Blood 1995, 86(4):1629-1635.
33. Ouachée-Chardin M., Elie C., de Saint Basile G., et al. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients. Pediatrics 2006, 117(4):e743-e750.
34. Filipovich A.H. Life-threatening hemophagocytic syndromes: current outcomes with hematopoietic stem cell transplantation. Pediatr Transplant 2005, 9(Suppl 7):87-91.
35. Connelly J.A., Choi S.W., Levine J.E. Hematopoietic stem cell transplantation for severe congenital neutropenia. Curr Opin Hematol 2012, 19(1):44-51.
36. Carlsson G., Winiarski J., Ljungman P., et al. Hematopoietic stem cell transplantation in severe congenital neutropenia. Pediatr Blood Cancer 2011, 56(3):444-451.
37. Mitsui-Sekinaka K., Imai K., Sato H., et al. Clinical features and hematopoietic stem cell transplantation for CD40 ligand deficiency in Japan. J Allergy Clin Immunol 2015, [pii:S0091-6749(15)00269-9] [Epub ahead of print].
38. Booth C., Gilmour K.C., Veys P., et al. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood 2011, 117(1):53-62.
39. Marsh R.A., Kim M.O., Liu C., et al. An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Biol Blood Marrow Transplant 2013, 19(11):1625-1631.
40. Marsh R.A., Rao K., Satwani P., et al. Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes. Blood 2013, 121(6):877-883.
41. Van Eyck L., Hershfield M.S., Pombal D., et al. Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency. J Allergy Clin Immunol 2015, 135(1):283-287.e5.
42. van Montfrans J., Zavialov A., Zhou Q. Mutant ADA2 in vasculopathies. N Engl J Med 2014, 371(5):478.
43. Patel N.C., Gallagher J.L., Torgerson T.R., et al. Successful haploidentical donor hematopoietic stem cell transplant and restoration of STAT3 function in an adolescent with autosomal dominant hyper-IgE syndrome. J Clin Immunol 2015, 35(5):479-485.
44. Goussetis E., Peristeri I., Kitra V., et al. Successful long-term immunologic reconstitution by allogeneic hematopoietic stem cell transplantation cures patients with autosomal dominant hyper-IgE syndrome. J Allergy Clin Immunol 2010, 126(2):392-394.
45. Arkwright P.D., Riley P., Hughes S.M., et al. Successful cure of C1q deficiency in human subjects treated with hematopoietic stem cell transplantation. J Allergy Clin Immunol 2014, 133(1):265-267.
46. Roifman C.M. Human IL-2 receptor alpha chain deficiency. Pediatr Res 2000, 48(1):6-11.
47. Engelhardt K.R., Shah N., Faizura-Yeop I., et al. Clinical outcome in IL-10- and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation. J Allergy Clin Immunol 2013, 131(3):825-830.
48. Kotlarz D., Beier R., Murugan D., et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology 2012, 143(2):347-355.
49. Seidel M.G., Hirschmugl T., Gamez-Diaz L., et al. Long-term remission after allogeneic hematopoietic stem cell transplantation in LPS-responsive beige-like anchor (LRBA) deficiency. J Allergy Clin Immunol 2015, 135(5):1384-1390.e1-8.
50. Albert M.H., Gennery A.R., Greil J., et al. Successful SCT for Nijmegen breakage syndrome. Bone Marrow Transplant 2010, 45(4):622-626.
51. Stray-Pedersen A., Backe P.H., Sorte H.S., et al. PGM3 mutations cause a congenital disorder of glycosylation with severe immunodeficiency and skeletal dysplasia. Am J Hum Genet 2014, 95(1):96-107.
52. Aldave J.C., Cachay E., Núñez L., et al. A 1-year-old girl with a gain-of-function STAT1 mutation treated with hematopoietic stem cell transplantation. J Clin Immunol 2013, 33(8):1273-1275.
53. Milner J.D., Vogel T.P., Forbes L., et al. Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood 2015, 125(4):591-599.
54. Kriván G., Erdos M., Kállay K., et al. Successful umbilical cord blood stem cell transplantation in a child with WHIM syndrome. Eur J Haematol 2010, 84(3):274-275.
55. Wehr C., Gennery A.R., Lindemans C., et al. Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency. J Allergy Clin Immunol 2015, 135(4):988-997.e6.
56. Janda A., Sedlacek P., Hönig M., et al. Multicenter survey on the outcome of transplantation of hematopoietic cells in patients with the complete form of DiGeorge anomaly. Blood 2010, 116(13):2229-2236.
57. Fish J.D., Duerst R.E., Gelfand E.W., et al. Challenges in the use of allogeneic hematopoietic SCT for ectodermal dysplasia with immune deficiency. Bone Marrow Transplant 2009, 43(3):217-221.
58. Schimke L.F., Rieber N., Rylaarsdam S., et al. A novel gain-of-function IKBA mutation underlies ectodermal dysplasia with immunodeficiency and polyendocrinopathy. J Clin Immunol 2013, 33(6):1088-1099.
59. Pai S.Y., Levy O., Jabara H.H., et al. Allogeneic transplantation successfully corrects immune defects, but not susceptibility to colitis, in a patient with nuclear factor-kappaB essential modulator deficiency. J Allergy Clin Immunol 2008, 122(6):1113-1118.e1.
60. Abu-Arja R.F., Chernin L.R., Abusin G., et al. Successful hematopoietic cell transplantation in a patient with X-linked agammaglobulinemia and acute myeloid leukemia. Pediatr Blood Cancer 2015, 62(9):1674-1676.
61. Albert M.H., Bittner T.C., Nonoyama S., et al. X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood 2010, 115(16):3231-3238.
62. Oshima K., Imai K., Albert M.H., et al. Hematopoietic stem cell transplantation for X-linked thrombocytopenia with mutations in the WAS gene. J Clin Immunol 2014, 35(1):15-21.